News Update: MSD's $9.2bn deal for flu biotech Cidara confirmed MSD has signed a $9.2 billion takeover deal for Cidara that will bolt on a universal flu prevention candidate in phase 3.
Market Access FT Summit: How Is U.S. Policy Reshaping the UK and EU Pharma... For the Financial Times (FT) Global Pharma & Biotech Summit in London 2025, pharmaphorum is providing coverage courtesy of NAVLIN Daily.
News AHA: MSD's oral PCSK9 matches injectables MSD closes on filing for enlicitide, a PCSK9 inhibitor that could offer the efficacy of injectables with the ease of a once-daily pill.
News Eisai settles Lenvima patent dispute with Torrent Pharma A settlement between Eisai and Torrent Pharma will keep a generic version of blockbuster cancer drug Lenvima off the US market until 2030.
News MSD still seeking deals 'with urgency' after Verona takeover MSD has only just completed its $10 billion takeover of Verona Pharma, but is still on the hunt for more bolt-on acquisitions.
News MSD, Eisai abandon combination trial in liver cancer MSD and Eisai's oncology partnership has had mixed fortunes this week, with a disappointment in liver cancer and encouraging data in kidney cancer.
News Filmmaker helps AbbVie spread the word about leukaemia AbbVie has turned to an award-winning documentary director to help it highlight the lives of people living with chronic lymphocytic leukaemia.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
